Effects of triiodothyronine and imipramine on basal 5-HT levels and 5-HT1 autoreceptor activity in rat cortex

European Journal of Pharmacology

Volumn 457, Issue 1, 2002, Pages 37-43

  Gur, Eitan ^a   Lifschytz, Tsuri ^a   Lerer, Bernard ^a   Newman, Michael E ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

5 HT (5 hydroxytryptamine, serotonin); 5 HT1A receptor; 5 HT1B receptor; Antidepressant; Triiodothyronine

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; AUTORECEPTOR; IMIPRAMINE; LIOTHYRONINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1 RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FRONTAL CORTEX; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; ANIMAL; BRAIN CORTEX; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AUTORECEPTORS; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; IMIPRAMINE; MALE; RATS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN; SEROTONIN AGONISTS; TRIIODOTHYRONINE;

EID: 0037073601     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02642-0     Document Type: Article

References (28)

1. Altshuler L.L., Bauer M., Frye M.A., Gitlin M.J., Mintz J., Szuba M.P., Leight K.L., Whybrow P.C. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am. J. Psychiatr. 158:2001;1617-1622.
2. Aronson R., Offman H.J., Joffe R.T., Naylor D. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch. Gen. Psychiatry. 53:1996;842-848.
3. 1A antagonists. Trends Neurosci. 19:1996;378-383.
4. Artigas F., Celada P., Laruelle M., Adell A. How does pindolol improve antidepressant action? Trends Pharmacol. Sci. 22:2000;224-228.
5. Auerbach S.B., Hjorth S. Effect of chronic administration of the selective serotonin uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;597-606.
6. Bauer M., Whybrow P.C. Thyroid hormone, neural tissue and mood modulation. World J. Biol. Psychiat. 2:2001;57-67.
7. Bauer M., Heinz A., Whybrow P.C. Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Mol. Psychiatry. 7:2002;140-156.
8. Bel N., Artigas F. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function: microdialysis studies. J. Pharmacol. Exp. Ther. 278:1996;1064-1072.
9. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15:1994;220-226.
10. Blier P., de Montigny C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol. Psychiatry. 44:1998;313-323.
11. 1A receptors control 5-HT release in the rat medial prefrontal cortex. NeuroReport. 10:1999;1441-1445.
12. Cleare A.J., McGregor A., O'Keane V. Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clin. Endocrinol. 43:1995;713-719.
13. Cleare A.J., McGregor A., Chambers S.M., Dawling S., O'Keane V. Thyroxine replacement increases central 5-hydroxytryptamine activity and reduces depressive symptoms in hypothyroidism. Neuroendocrinology. 64:1996;65-69.
14. Cremers T.I.F.H., Spoelstra E.N., De Boer P., Bosker F.J., Mork A., Den Boer J., Westerink B.H.C., Wikstrom H.V. Desensitization of 5-HT autoreceptors upon pharmacokinetically monitored chronic treatment with citalopram. Eur. J. Pharmacol. 397:2000;351-357.
15. Dawson L.A., Nguyen H.Q., Smith D.I., Schechter L.E. Effects of chronic fluoxetine treatment in the presence and absence of (±)-pindolol: a microdialysis study. Br. J. Pharmacol. 130:2000;797-804.
16. Dremencov E., Gur E., Lerer B., Newman M.E. Subchronic fluoxetine administration to rats: effects on 5-HT autoreceptor activity as measured by in vivo microdialysis. Eur. Neuropsychopharmacol. 10:2000;229-236.
17. Gur E., Lerer B., Newman M.E. Chronic clomipramine and triiodothyronine increase 5-HT levels in rat frontal cortex in vivo: relationship to 5-HT autoreceptor activity. J. Pharmacol. Exp. Ther. 288:1999;81-87.
18. Gur E., Dremencov E., Lerer B., Newman M.E. Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo. Eur. J. Pharmacol. 372:1999;17-24.
19. Gur E., Dremencov E., Van de Kar L.D., Lerer B., Newman M.E. Effects of chronically administered venlafaxine on 5-HT receptor activity in rat hippocampus and hypothalamus. Eur. J. Pharmacol. 436:2002;57-65.
20. 1A receptors by lithium addition to antidepressant treatments. Neuropsychopharmacology. 22:2000;346-356.
21. 1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br. J. Pharmacol. 126:1999;1741-1750.
22. Heal D.J., Smith S.L. The effects of acute and repeated administration of T3 to mice on 5-HT-1 and 5-HT-2 function in the brain and its influence on the actions of repeated electroconvulsive shock. Neuropharmacology. 27:1988;1239-1248.
23. 1A receptors. Eur. J. Pharmacol. 60:1994;243-246.
24. 2A receptors in adult rat brain. Neuropsychopharmacology. 24:2001;652-662.
25. Newman M.E., Shapira B., Lerer B. Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: a critical review. Int. J. Neuropsychopharmacol. 1:1998;49-69.
26. Newman M.E., Agid O., Gur E., Lerer B. Pharmacological mechanisms of T3 augmentation of antidepressant action. Int. J. Neuropsychopharmacol. 3:2000;187-191.
27. Prange A.J. Novel uses of thyroid hormones in patients with affective disorders. Thyroid. 6:1996;537-543.
28. 1B autoreceptor function in the anterior hypothalamus in vivo: effect of chronic antidepressant treatment. Br. J. Pharmacol. 126:1999;1777-1784.